FULC
Fulcrum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
+1.37%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -5.9%
- EBIT
- -2.2%
- EPS
- +0.8%
- Free cash flow
- -1.4%
- Operating cash flow
- -1.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +22.6%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026